Canadian Markets closed

Merck & Co., Inc. (MRK)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
62.57-0.06 (-0.10%)
At close: 4:00PM EDT

62.00 -0.57 (-0.91%)
After hours: 7:54PM EDT

People also watch
PFEJNJBMYLLYPG
Full screen
Previous Close62.63
Open62.54
Bid0.00 x
Ask0.00 x
Day's Range62.50 - 62.90
52 Week Range57.18 - 66.80
Volume7,783,692
Avg. Volume8,843,779
Market Cap171.14B
Beta0.97
PE Ratio (TTM)39.88
EPS (TTM)1.57
Earnings DateJul 28, 2017
Dividend & Yield1.88 (3.00%)
Ex-Dividend Date2017-06-13
1y Target Est69.70
Trade prices are not sourced from all markets
  • Reuters2 hours ago

    Merck immunotherapy fails to improve survival in head and neck cancer

    Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. The drug, which blocks a mechanism tumors use to hide from the immune system allowing it to recognize and attack the cancer, won accelerated U.S. approval last August for these patients based on its ability to shrink tumors. As a condition of the accelerated approval, Merck was required to conduct a trial to demonstrate superiority over standard treatment and verify the clinical benefit of Keytruda in this patient population.

  • Business Wire4 hours ago

    Merck Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

    Merck , known as MSD outside the United States and Canada, today announced that the pivotal phase 3 KEYNOTE-040 trial investigating KEYTRUDA® , the company’s anti-PD-1 therapy, in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma did not meet its pre-specified primary endpoint of overall survival . The safety profile observed in KEYNOTE-040 was consistent ...

  • Benzinga5 hours ago

    Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

    Pharmaceutical giants Bristol-Myers Squibb Co (NYSE: BMY ) and Merck & Co., Inc. (NYSE: MRK ) both release their second quarter earnings reports this week. According to BMO Capital, investors should be ...